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Clostridium diﬃ  cile is the most burdensome gastro-
intestinal infection and one of the main infectious 
causes of morbidity and mortality in industrialised 
countries.1 Prevention of C diﬃ  cile infection relies on 
methods to reduce transmission of the pathogen, 
through eﬀ ective hand hygiene, barrier precautions, 
isolation of patients, and environmental cleaning. Per-
haps even more important are attempts to reduce host 
susceptibility to infection by decreasing unneces sary 
antibiotic use.2 Antibiotic use disrupts and depletes the 
normal gastrointestinal ﬂ ora, allowing C diﬃ  cile to thrive 
and generate clinical disease.3
When antibiotic treatment is unavoidable, reinforce-
ment of the colonic ﬂ ora might be another means to 
decrease susceptibility of patients to C diﬃ  cile. Deﬁ ni-
tive restoration of the colonic ecosystem through stool 
transfer has unequivocal beneﬁ t in treatment of estab-
lished C diﬃ  cile infections and prevention of recurrences.4 
A more palatable, or at least less pungent, approach to 
boost colonic defences is the use of non-pathogenic 
microbial supplements—known as pro biotics. Probiotics 
have been widely marketed in commercial preparations, 
and widely studied as a means to prevent C diﬃ  cile. Two 
recent meta-analyses have sum marised the results of 
previous trials, detecting large reductions in the risk of 
antibiotic-associated diar rhoea (AAD) in general (relative 
risk [RR] 0·58, 95% CI 0·50–0·68)5 and C diﬃ  cile infections 
in particular (0·34, 0·24–0·49).6 These impressive eﬀ ect 
sizes are motivating many health-care institutions to 
consider routine probiotic coadministration with anti-
biotic treatments.
However, in The Lancet, Stephen Allen and colleagues7 
question the usefulness of routine probiotics. Their 
PLACIDE trial, done at ﬁ ve centres in England and 
Wales, is the largest trial to be reported in this 
discipline (n=2941). The study is rigorous, with central 
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health care are to be universal human rights, then we 
need to understand how unfair the distribution is of both 
health status and health services.
Second, examination of the equitable distribution of key 
indicators of social determinants of health. I propose four: 
early child development at age 5 years; the proportion 
of young people not in employment, education, or 
training; an adult poverty measure; and a measure of 
social isolation or poverty or both in people older than 
working age. Problems of international comparability 
will arise, but these are soluble, as shown by the Human 
Development Reports or regular World Bank reports.
Personally, I would not stop there. I would want the 
monitoring framework to include inequities in power, 
money, and resources—the structural drivers of health 
inequity highlighted by the Commission on Social 
Determinants of Health. For example, in London, 
UK the eﬀ ects of the economic downturn on health 
equity will be monitored by indicators of employment, 
economic security, housing, and migration. Although 
these are all important, the four areas I have proposed 
are eminently doable, and should be done, by any 
country that is serious not just about ensuring uni-
versal coverage of health services but equity in health 
of its population.
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randomisation, use of placebo control, careful allocation 
concealment, and thorough follow-up for evidence of 
AAD or C diﬃ  cile diarrhoea (CDD). A 21-day treatment 
with a combined preparation of lactobacilli and biﬁ do-
bacteria neither reduced the risk of AAD (RR 1·04, 
95% CI 0·84–1·28) nor that of CDD (0·71, 0·34–1·47).
How do we reconcile the large negative PLACIDE trial 
with the large positive eﬀ ects detected in previous 
meta-analyses, especially since the sample size in 
PLACIDE dwarfs that of any previous studies in the 
discipline?6 To address this notion, I recreated the forest 
plot from the previous meta-analysis of the eﬀ ect 
of probiotic use on the outcome of C diﬃ  cile infec-
tion (ﬁ gure; Review Manager, version 5.1, Cochrane 
Collaboration, Copenhagen, Denmark). The 95% CIs of 
the PLACIDE result visually overlap those of previous 
studies, and there is no statistical evidence of additional 
heterogeneity (I²=0). Importantly, addition of the 
PLACIDE results barely shifts the risk reduction estimate, 
from 0·34 (95% CI 0·24–0·49) to 0·39 (0·29–0·54). 
Although the sample size of PLACIDE was very large, 
the event rate was much lower than predicted (about 
10% occurrence of ADD compared with a prediction of 
20%; 1% occurrence of CDD compared with a prediction 
of 4%).7 Perhaps the PLACIDE trial was negative 
because its 95% CIs were unable to rule out a potential 
16% reduction in occurrence of AAD and a potential 
66% reduction in CDD. 
Alternatively, maybe the results of this single large 
randomised trial should outweigh the results of any 
meta-analysis.8 Most previous probiotic research has 
involved small, single centre studies of variable quality. 
Even when a meta-analysis is carefully done, it is limited 
by the quality of included studies, and might introduce 
additional bias through study selection and data pooling 
methods.9 A third of meta-analyses do not accurately 
predict the results of subsequent large randomised 
controlled trials and, generally, a well done trial serves as 
the gold standard of evidence.8
At the very least, the low absolute risk reductions in 
PLACIDE question the cost-eﬀ ectiveness of probiotics. 
A cost–consequence analysis funded by a probiotic 
manufacturer established that the incidence of CDD 
must be more than 1·2% for this strategy to produce cost 
Figure: Forest plot for eﬃ  cacy of probiotic supplements in prevention of Clostidium diﬃ  cile infection
NE=not estimable. 
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Age-related macular degeneration is the leading cause 
of blindness in developed countries.1 Since the mid-
2000s, intraocular injections of agents inhibiting vascu-
lar endothelial growth factor (VEGF) have become the 
mainstay of treatment for neovascular (wet) age-related 
macular degeneration.2–4 Emerging data from national 
registries show that blindness related to age-related 
macular degeneration started to fall when anti-VEGF 
treatment was introduced.5 
However, three key questions remain unanswered 
for physicians, their patients, and policy makers. 
First, what is the most cost-eﬀ ective drug? Two anti-
VEGF agents are available: ranibizumab, which was 
approved by the US Food and Drug Administration, 
and bevacizumab, which is a cancer drug widely used 
oﬀ  label.1 Bevacizumab costs a fraction of ranibizumab, 
and is the main drug used in many non-reimbursed 
settings, such as in US practice.6 A report6 suggested 
that US Medicare could save more than US$1 billion 
within 2 years if bevacizumab replaced ranibizumab. 
Second, how often should injections be given? Initial 
clinical trials3,4 suggested that ranibizumab should be 
given monthly for the best visual outcome. In clinical 
practice, physicians and patients would obviously 
prefer injections with intervals of longer than 1 month, 
and alternative regimens (eg, as needed) have been 
proposed. However, whether such alternative regimens 
have acceptable results is unclear. Third, does long-
term treatment have safety issues? Although anti-
VEGF agents are injected in small quantities into the 
eye, concerns about systemic safety have been raised, 
including possible risk of stroke.7,8
In The Lancet, Usha Chakravarthy and colleagues report 
2-year ﬁ ndings of the IVAN randomised controlled trial.9 
This trial, along with the US CATT trial,10,11 attempts to 
answer these questions. In IVAN, adults with untreated 
neovascular age-related macular degeneration were 
randomly assigned to receive intravitreal injections of 
ranibizumab or bevacizumab in continuous (monthly) 
or discontinuous (as needed) regimens.12 Unfortunately, 
the results have not clariﬁ ed the situation. For best 
corrected distance visual acuity—the primary outcome—
bevacizumab was neither non-inferior nor inferior to 
ranibizumab (mean diﬀ erence –1·37 letters in favour of 
ranibizumab, 95% CI –3·75 to 1·01; prespeciﬁ ed non-
inferiority limit 3·5 letters).9 Similarly, discontinuous 
treatment was neither non-inferior nor inferior to con-
tinuous treatment (–1·63 letters in favour of continuous 
treatment, –4·01 to 0·75).9 Can the three questions now 
be answered? 
Treatment of age-related macular degeneration 
savings.10 At my own centre, the percentage of antibiotic 
recipients who develop CDD is right at this boundary, and 
so any shift in eﬀ ect size could tip decision preferences.
PLACIDE is a large and rigorous negative study, and we 
must judge whether it can tip the balance of probiotic 
evidence. Similarly, lactobacilli and biﬁ dobacteria are 
only two types of non-pathogenic bacteria, and we 
must consider whether they can really tip the balance of 
a diverse gut ecosystem.11
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